Table 1.
Baseline clinical characteristics of the included patients (n = 51).
| Characteristics | Patients |
|---|---|
| Gender | |
| Male | 47 (92.2%) |
| Female | 4 (7.8%) |
| Age | 56.1 ± 10.7 |
| ECOG grade | |
| 0 | 32 (62.7%) |
| 1 | 19 (37.3%) |
| Etiology | |
| HBV | 38 (74.5%) |
| HCV | 4 (7.8%) |
| Other reasons | 9 (17.6%) |
| Cirrhosis | 46 (90.2%) |
| Total bilirubin | |
| ≥34umol/L | 9 (17.6%) |
| <34umol/L | 42 (82.4%) |
| Hypoproteinemia | 22 (43.1%) |
| Child-Pugh | |
| A | 29 (56.9%) |
| B | 22 (43.1%) |
| PVTT 35 (68.6%) | |
| Vp 1 | 10 (28.6%) |
| Vp 2 | 17 (48.6%) |
| Vp 3 | 8 (22.8%) |
| Number of tumors | |
| Single | 24 (47.1%) |
| Multiple | 27 (52.9%) |
| Tumor diameter | |
| ≥5cm | 40 (78.4%) |
| <5cm | 11 (21.6%) |
| AFP | |
| ≥400ng/mL | 28 (54.9%) |
| <400ng/mL | 23 (45.1%) |
| BCLC | |
| A | 2 (3.9%) |
| B | 11 (21.6%) |
| C | 38 (74.5%) |
| Surgical conversion | 13 (25.5%) |
HBV, hepatitis b virus; HCV, hepatitis c virus; PVTT, portal vein tumor thrombus; AFP, α-fetoprotein; BCLC, barcelona clinic liver cancer.